HK1219222A1 - 包含降血脂藥的製劑 - Google Patents

包含降血脂藥的製劑

Info

Publication number
HK1219222A1
HK1219222A1 HK16107193.2A HK16107193A HK1219222A1 HK 1219222 A1 HK1219222 A1 HK 1219222A1 HK 16107193 A HK16107193 A HK 16107193A HK 1219222 A1 HK1219222 A1 HK 1219222A1
Authority
HK
Hong Kong
Prior art keywords
formulation
hypolipidemic agent
hypolipidemic
agent
Prior art date
Application number
HK16107193.2A
Other languages
English (en)
Chinese (zh)
Inventor
Jitendre D Patel
Prakash Davadra
Snehal Patel
Shafiq Sheikh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of HK1219222A1 publication Critical patent/HK1219222A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16107193.2A 2013-07-25 2016-06-21 包含降血脂藥的製劑 HK1219222A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (et) 2013-07-25 2013-07-25
PCT/IN2014/000489 WO2015011730A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Publications (1)

Publication Number Publication Date
HK1219222A1 true HK1219222A1 (zh) 2017-03-31

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107193.2A HK1219222A1 (zh) 2013-07-25 2016-06-21 包含降血脂藥的製劑

Country Status (21)

Country Link
US (2) US9610277B2 (et)
EP (1) EP3024446A1 (et)
JP (1) JP2016523895A (et)
KR (1) KR101786843B1 (et)
CN (1) CN105407873A (et)
AP (1) AP2015008876A0 (et)
AR (1) AR097067A1 (et)
AU (1) AU2014294548B2 (et)
BR (1) BR112015031878A2 (et)
CA (1) CA2917923A1 (et)
EA (1) EA201690072A1 (et)
HK (1) HK1219222A1 (et)
IN (1) IN2013MU02470A (et)
MA (1) MA38865A1 (et)
MX (1) MX2015016971A (et)
NZ (1) NZ714558A (et)
PH (1) PH12015502802A1 (et)
SG (1) SG11201509798PA (et)
TW (1) TW201545773A (et)
WO (1) WO2015011730A1 (et)
ZA (1) ZA201508682B (et)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101427486B (zh) 2006-05-23 2013-06-19 英特尔公司 具有定向天线和一个或多个毫米波反射器的毫米波通信系统
CA2825456C (en) 2011-01-31 2016-01-05 Cadila Healthcare Limited Treatment for lipodystrophy
CN105377246B (zh) 2013-04-22 2018-03-20 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (et) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
BR112019011740A2 (pt) 2016-12-09 2019-10-29 Cadila Healthcare Ltd composição farmacêutica e método para o tratamento de colangite biliar primária
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL176885B1 (pl) 1992-07-03 1999-08-31 Smithkline Beecham Plc Kompozycja farmaceutyczna
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
TW480262B (en) 1995-04-28 2002-03-21 Daiichi Seiyaku Co A taxol derivative having an antitumor activity and a pharmaceutical composition comprising the same
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
DE69828445D1 (de) 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
EP1082313A1 (en) 1998-05-27 2001-03-14 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
KR100649304B1 (ko) 2000-01-19 2006-11-24 카딜라 헬스케어 리미티드 저지방혈증, 저콜레스테롤혈증 활성을 가지는 신규화합물, 그 제조방법 및 이를 포함하는 제약학적 조성물
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
DE602007009489D1 (de) * 2006-02-22 2010-11-11 Eisai R&D Man Co Ltd Stabilisierte pharmazeutische zusammensetzung
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
ES2681794T3 (es) 2009-11-26 2018-09-17 Genfit Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
BR112013008985A2 (pt) * 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
CA2825456C (en) * 2011-01-31 2016-01-05 Cadila Healthcare Limited Treatment for lipodystrophy
CN105377246B (zh) * 2013-04-22 2018-03-20 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (et) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives

Also Published As

Publication number Publication date
US20170266158A1 (en) 2017-09-21
KR101786843B1 (ko) 2017-10-18
AU2014294548B2 (en) 2017-08-10
AP2015008876A0 (en) 2015-11-30
WO2015011730A1 (en) 2015-01-29
IN2013MU02470A (et) 2015-06-26
CN105407873A (zh) 2016-03-16
PH12015502802A1 (en) 2016-03-14
SG11201509798PA (en) 2016-02-26
NZ714558A (en) 2017-02-24
MA38865A1 (fr) 2017-12-29
TW201545773A (zh) 2015-12-16
AU2014294548A1 (en) 2015-12-17
EA201690072A1 (ru) 2016-06-30
MX2015016971A (es) 2016-04-25
US9610277B2 (en) 2017-04-04
ZA201508682B (en) 2017-03-29
US20160136131A1 (en) 2016-05-19
AR097067A1 (es) 2016-02-17
JP2016523895A (ja) 2016-08-12
EP3024446A1 (en) 2016-06-01
BR112015031878A2 (pt) 2017-07-25
US10098868B2 (en) 2018-10-16
CA2917923A1 (en) 2015-01-29
KR20160013150A (ko) 2016-02-03

Similar Documents

Publication Publication Date Title
HK1219222A1 (zh) 包含降血脂藥的製劑
EP2956781A4 (en) RECHARGE BLOCK
GB201304784D0 (en) Dispenser
EP2968569A4 (en) COUGAR FORMULATION
GB2510428B (en) Glove dispenser
GB201317990D0 (en) A conncetor
GB201320432D0 (en) Novel formulation
EP2992813A4 (en) LIQUID DETECTION INSTRUMENT
GB2515360B (en) Dispenser
EP2952799A4 (en) PIPE REINFORCING ELEMENT
RS58856B1 (sr) Nova stabilna formulacija
GB201322948D0 (en) Improved formulation
SG11201604752SA (en) Antibacterial peptide-inducing agent
EP2958828A4 (de) Spender
ZA201505008B (en) Cleaning agent
HUE060750T2 (hu) Fluorozó-szerek
GB2517232B (en) Formulation
GB201317718D0 (en) Novel formulation
TWI563390B (en) Completion packet return
EP3037100A4 (en) MEANS TO PREVENT MUSCLE ATROPHY
HK1209981A1 (en) Formulation
GB201312347D0 (en) Formulation
GB201312761D0 (en) A composition
GB201313018D0 (en) A Composition for anti-microbial use
GB201306657D0 (en) Trestle